Similar articles

• Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction.

  Uyar I, Mansuroğlu D, Kirali K, Erentuğ V, Bozbuğa NU, Uysal G, Yakut C. Uyar I, et al. J Card Surg. 2005 Jul-Aug;20(4):337-44. doi: 10.1111/j.1540-8191.2005.200355.x. J Card Surg. 2005. PMID: 15985134 Clinical Trial.
• Metabolic therapy in cardiac surgery--"Optimizing the engine's fuel supply and more...".

  Doenst T, Amorim PA. Doenst T, et al. Scand Cardiovasc J. 2010 Feb;44(1):4-8. doi: 10.3109/14017430903469928. Scand Cardiovasc J. 2010. PMID: 20141343 No abstract available.
• Long-term outcome after coronary artery bypass grafting in patients with left ventricular dysfunction: does the type of cardioplegia matter?

  Ibrahim MF, Refaat AA. Ibrahim MF, et al. Interact Cardiovasc Thorac Surg. 2008 May;7(3):498. doi: 10.1510/icvts.2008.178343A. Interact Cardiovasc Thorac Surg. 2008. PMID: 18495725 No abstract available.
• Potential cardiovascular applications of glutamate, aspartate, and other amino acids.

  Arsenian M. Arsenian M. Clin Cardiol. 1998 Sep;21(9):620-4. doi: 10.1002/clc.4960210904. Clin Cardiol. 1998. PMID: 9755377 Free PMC article. Review.
• Preserving left ventricular function during percutaneous coronary intervention.

  Banerjee P, Card D. Banerjee P, et al. J Invasive Cardiol. 2007 Oct;19(10):440-3. J Invasive Cardiol. 2007. PMID: 17906347 Review.